GlobeNewswire by notified

Stolt-Nielsen Limited Reports Unaudited Results For the First Quarter of 2022


LONDON, March 31, 2022 – Stolt-Nielsen Limited (Oslo Børs: SNI) today reported unaudited results for the first quarter of 2022. The Company reported a first-quarter net profit attributable to shareholders of $52.3 million, with revenue of $606.2 million, compared with a net profit of $35.0 million, with revenue of $593.1 million, in the fourth-quarter 2021.

Highlights for the first quarter, compared with the fourth quarter of 2021, were:

  • Stolt Tankers reported operating profit of $25.0 million, up from $19.2 million as rising bunker prices were more than offset by bunker surcharges and higher spot freight rates.  
  • The Stolt Tankers Joint Service (STJS) Sailed-in Time-Charter Index increased marginally from 0.51 to 0.52. The STJS sailed-in revenue for the quarter was $18,786 per operating day based on an average ship size of 31,717 deadweight tonnes (DWT), marginally up from $18,438.
  • Stolthaven Terminals reported operating profit of $22.0 million, up from $8.4 million. Besides a prior quarter negative impact of a $10.0 million impairment, the improvement in results was largely driven by higher throughput and storage revenue following an increase in utilisation.
  • Stolt Tank Containers reported operating profit of $40.0 million, up from $36.4 million, reflecting improved transportation margin and higher demurrage revenue.
  • Stolt Sea Farm reported an operating profit, before fair value adjustment of biomass, of $6.5 million compared with $5.3 million, reflecting continued high volumes and firm sales prices for both turbot and sole.
  • Stolt-Nielsen Gas reported operating profit of $3.6 million, compared to $1.8 million. The previous quarter included a gain on sale of land in Canada of $3.2 million, while the first quarter included $4.7 million as our share of a gain on the sale of a 20,000-cbm newbuilding by Avenir.
  • Corporate and Other reported an operating loss of $4.7 million compared with a loss of $0.1 million. The increase was due to higher profit sharing and other employee benefit expenses.

Niels G. Stolt-Nielsen, Chief Executive Officer of Stolt-Nielsen Limited, commented: “Typically the first quarter of the year is the seasonally weakest quarter for our businesses. However, this year the first quarter showed no signs of weakness as we posted our strongest quarterly results since 2008, with Stolt Tank Containers leading the way with record earnings. Although shipment volumes were down, margins held firm, supported by our ability to secure space on container ships and higher demurrage revenue. At Stolt Tankers firmer spot rates helped offset higher bunker cost, and subsequent to quarter-end it appears that spot rates continue to match the increase in bunker cost. Increased utilisation and throughput volume at Stolthaven Terminals resulted in higher revenue and margins. And at Stolt Sea Farm, contrary to normal seasonal patterns where we usually experience a drop in prices and volume during January and February, sales volumes have held up very well. We were consequently able to maintain prices throughout the quarter.

“Just as we thought life would go back to “normal” after the pandemic, war breaks out in Ukraine.  The central banks are raising interest rates, trying to curb inflation. Oil and gas prices are skyrocketing and a new outbreak of Covid is lurking in China. I can’t imagine a more difficult environment to give a quarterly guidance, but let me try. There have been no further newbuilding orders in the chemical tanker space.  There is a drive to secure refined products away from Russia causing longer tonne-mile demand in the MR market resulting in swing tonnage beginning to exit the chemical trade.  In times of uncertainty the product and chemical markets tend to secure additional storage capacity, so we predict a strengthening of utilisation and rates in Stolthaven Terminals. I expect shipments in Stolt Tank Containers to come down because of the demand destruction caused by the high container liner rates. The value of some of the products we carry in STC cannot justify these increased rates and the products could possibly move back to chemical tankers.  However, I still believe margin and shipment volumes will give a record year for STC. I expect Stolt Sea Farm to have a similar year as in 2021.

“On March 7th we announced the purchase of 5% of the A-shares in Odfjell SE. This investment is driven by our belief in the chemical tanker industry and a pending recovery. Our investment has naturally prompted speculation about a potential merger between Stolt Tankers and Odfjell Tankers. I have previously spoken out about the need for consolidation in the chemical tanker industry and still strongly believe it is the best way to make our industry environmentally and economically sustainable.”

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Vallourec first quarter 2022 results - New initiatives launched to be cycle-proof18.5.2022 18:15:00 CEST | Press release

Meudon (France), May 18, 2022 Vallourec first quarter 2022 results New initiativeslaunched to be cycle-proof Q1 2022 results in line with expectations €916 million revenue, a 30% year-over-year increase led by North America€45 million reported EBITDA negatively impacted by the iron ore mine shutdown; normalized level of ~€130 million1€(230) million Free Cash Flow impacted by €(217) million working capital build-up reflecting higher forward volume expectations and raw material price increases FY 2022 EBITDA now expected to be significantly above 2021, despite Q1 impacted by mine shutdown €230million of recurring EBITDA and €250million ongoing cash up-lift (+€100million compared to November 2021 announcement) Launching the closure process of German sites and refocusing European plantsStreamline corporate structure to better manage a reshaped industrial footprint and a leaner organization Philippe Guillemot, Chairman of the Board of Directors and Chief Executive Officer, declared: “Steppi

Changes in financial results publication18.5.2022 18:01:16 CEST | Press release

PRFoods AS declares that 2021/2022 financial year 9 months unaudited results will be published, according to Stock Exchange rules no later than two months after end of the reporting period, 31.5.2022. Although interim report will be unaudited, PRFoods has required a third party assessment of the impact of sale of Heimon Kala Oy, taking into account that final purchase price is dependent on certain conditions subsequent presumed to be met before publication. Indrek Kasela AS PRFoods Member of the Management Board Phone: +372 452 1470


WRC GENERATIONS: THE MOST COMPLETE RALLY GAME IS COMING IN OCTOBER! Lesquin, 18th May 2022 - NACON and the studio KT Racing are pleased to announce their new rally game, WRC Generations, the official video game of the FIA World Rally Championship, scheduled for release in Autumn 2022 on PlayStation®4, PlayStation®5, Xbox One, Xbox Series X|S, Nintendo Switch and Steam for PC. The result of 7 years of collaboration with legendary drivers, who have already made WRC 10 and WRC 9 the references of the genre, the latest entry in the series is an authentic and comprehensive rally racing simulation, giving players the chance to drive powerful cars in the most famous rallies of all time! Check out the announcement trailer for WRC Generations: [link] An unrivalled level of realism Never before have games come this close to the real-life World Rally Championship! Hailed by both critics and professionals, this year's WRC simulation has been reinforced with numerous improvements and optimisations


NACON PRESENTS AN AMBITIOUS LINEUP AND ANNOUNCES TWO NEW GAMES NACON has confirmed its status as a major mid-publisher and creator of standard-setting accessories Paris (France), 18 May 2022 – The latest edition of Bigben Week opened its doors on Monday. This major event for the group is the perfect occasion to present its products and objectives to the media and international partners. NACON, the group's gaming brand, held a press conference to announce all of its news and to explain how it is changing. The last time the event was held – in 2019, due to the health crisis – BIGBEN presented its soaring ambitions for the years to come. Bigben Week is an opportunity to highlight the company's strong growth over the last three years along with the major changes it has undergone. AN EFFECTIVE STRATEGY NACON’s March 2020 listing on the stock market raised more than €100 million, reinforcing the company's ambitions and resources. Over the course of three years, NACON acquired no fewer than 9

FDA beviljar särläkemedelsstatus för tasquinimod vid behandling av myelofibros18.5.2022 15:00:00 CEST | Pressemelding

Lund 18 maj 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) meddelade idag att amerikanska Food and Drug Administration (FDA) har beviljat särläkemedelsstatus för tasquinimod vid behandling av myelofibros. "Särläkemedelsstatus som FDA tilldelat för tasquinimod i myelofibros utgör ett viktigt steg framåt för Active Biotech", säger Helén Tuvesson, VD Active Biotech. "Det öppnar en viktig regulatorisk väg och ger oss potential att snabbt avancera utvecklingen av tasquinimod i denna patientpopulation.” FDAs Orphan Drug Designation program ger särläkemedelsstatus för läkemedelskandidater avsedda för säker och effektiv behandling, diagnos eller förebyggande av ovanliga sjukdomar som drabbar färre än 200.000 människor i USA. Denna särläkemedelsstatus ger 7 års marknadsexklusivitet vid marknadsgodkännande samt vissa andra fördelar. I februari 2022 ingick Active Biotech ett exklusivt licensavtal med Oncode Institute i Nederländerna, som verkar på uppdrag av Erasmus University Medical Center (